David Heimbrook
Overview
Explore the profile of David Heimbrook including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
728
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Higgins B, Glenn K, Walz A, Tovar C, Filipovic Z, Hussain S, et al.
Clin Cancer Res
. 2014 May;
20(14):3742-52.
PMID: 24812409
Purpose: Antitumor clinical activity has been demonstrated for the MDM2 antagonist RG7112, but patient tolerability for the necessary daily dosing was poor. Here, utilizing RG7388, a second-generation nutlin with superior...
2.
Su F, Bradley W, Wang Q, Yang H, Xu L, Higgins B, et al.
Cancer Res
. 2011 Dec;
72(4):969-78.
PMID: 22205714
A high percentage of patients with BRAF(V600E) mutant melanomas respond to the selective RAF inhibitor vemurafenib (RG7204, PLX4032) but resistance eventually emerges. To better understand the mechanisms of resistance, we...
3.
Yang H, Higgins B, Kolinsky K, Packman K, Bradley W, Lee R, et al.
Cancer Res
. 2011 Dec;
72(3):779-89.
PMID: 22180495
The protein kinase BRAF is a key component of the RAS-RAF signaling pathway which plays an important role in regulating cell proliferation, differentiation, and survival. Mutations in BRAF at codon...
4.
Wang H, Daouti S, Li W, Wen Y, Rizzo C, Higgins B, et al.
Cancer Res
. 2011 Jun;
71(16):5535-45.
PMID: 21705440
Although targeting the Ras/Raf/MEK pathway remains a promising anticancer strategy, mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitors in clinical development are likely to be limited in their ability to...
5.
He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X, et al.
Mol Oncol
. 2011 Feb;
5(3):292-301.
PMID: 21315665
Interest continues to build around the early application of patient selection markers to prospectively identify patients likely to show clinical benefit from cancer therapies. Hypothesis generation and clinical strategies often...
6.
Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al.
Cancer Res
. 2010 Jun;
70(13):5518-27.
PMID: 20551065
The BRAF(V600E) mutation is common in several human cancers, especially melanoma. RG7204 (PLX4032) is a small-molecule inhibitor of BRAF(V600E) kinase activity that is in phase II and phase III clinical...
7.
Daouti S, Higgins B, Kolinsky K, Packman K, Wang H, Rizzo C, et al.
Mol Cancer Ther
. 2010 Jan;
9(1):134-44.
PMID: 20053779
Targeting the Ras/Raf/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway represents a promising anticancer strategy. Recently, we have reported a novel class of potent and selective non-ATP-competitive MEK1/2 inhibitors...
8.
Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, et al.
Cancer Res
. 2009 Sep;
69(19):7672-80.
PMID: 19773430
Notch signaling is an area of great interest in oncology. RO4929097 is a potent and selective inhibitor of gamma-secretase, producing inhibitory activity of Notch signaling in tumor cells. The RO4929097...
9.
Kolinsky K, Zhang Y, Dugan U, Heimbrook D, Packman K, Higgins B
Anticancer Res
. 2009 Apr;
29(1):91-8.
PMID: 19331137
Background: Xenograft and mathematical models have shown that the antitumor activity of capecitabine can be increased by modifying the schedule from 14 days on, 7 off (14/7) to 7/7. Materials...
10.
Daouti S, Wang H, Li W, Higgins B, Kolinsky K, Packman K, et al.
Cancer Res
. 2009 Feb;
69(5):1924-32.
PMID: 19244124
The mitogen-activated protein kinase (MAPK) signal transduction pathway plays a central role in regulating tumor cell growth, survival, differentiation, and angiogenesis. The key components of the Ras/Raf/MEK/ERK signal module are...